AestheticsFeatured Articles

Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement

By August 25, 2020No Comments

Featured Article

Featured Article

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Read more

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Michelle E. Walters MD, Delphine J. Lee MD PhD, Paul S. Yamauchi MD PhD

Psoriasis is a chronic skin condition with a negative impact on patient quality of life. The National Psoriasis Foundation states that an acceptable response to psoriasis treatment is at least a 75% reduction in body surface area (BSA) at 3 months after initiation of treatment.

This reduction in BSA has been associated with improvement in quality of life, with clearance rates of clear to almost clear leading to an even greater improvement in quality of life.2,3 To date, there have been no studies examining the relationship between improvement in quality of life following a reduction in BSA, and the increased utilization of cosmetic procedures. Here, we examine the relationship between quality of life and the use of various cosmetic procedures in patients treated for psoriasis with systemic and biologic therapies who achieved at least 75% reduction in BSA.

This was a retrospective study assessing quality of life and the use of cosmetic procedures in psoriasis patients after attaining a75% or greater reduction of the body surface area with biologic agents only, systemic agents only, or a combination of both. This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki. All patients provided informed consent.

Read Full Article Now
Article Cited in this Post

You May Also Like

Journal of Drugs in Dermatology JDD Article about GLP-1 Receptor Agonists in Overweight and Obese Patients With Hidradenitis Suppurativa

GLP-1 Receptor Agonists in Overweight and Obese Patients With Hidradenitis Suppurativa

| Featured Articles, Hidradenitis Suppurativa, Latest News | No Comments
GLP-1 Receptor Agonist Use and Hidradenitis Suppurativa in Overweight Patients — Retrospective Findings from a Single Center Have you read this article in the latest JDD issue? A recent IRB-exempt…
Journal of Drugs in Dermatology JDD Article about Rural Health Disparities in Skin Cancer Amplified Among Skin of Color

Non-Invasive Diagnosis of Sun Damaged Skin: Actinic Keratosis Vs Squamous Cell Carcinoma

| Featured Articles, Latest News, Skin Cancer, Skin of Color | No Comments
From the Vault: In this article from JDD, a multi state BRFSS analysis finds higher skin cancer history in rural populations and In this article from the JDD vault, authors…
Journal of Drugs in Dermatology JDD Article about Treatment Strategy for Refractory Dissecting Cellulitis of the Scalp Using Bimekizumab, Isotretinoin, and Oral Antibiotics

Treatment Strategy for Refractory Dissecting Cellulitis of the Scalp Using Bimekizumab, Isotretinoin, and Oral Antibiotics

| Case Reports, Featured Articles, Latest News | No Comments
Have you read this JDD case report on combination therapy for dissecting cellulitis of the scalp? Have you read this article in JDD? This case report describes two men, ages…

Leave a Reply